Thomas Metzner

Mr. Thomas Metzner

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TMThomas Metzner
Thomas Metzner
DLDeborah R. Leitner
Deborah R. Leitner
KMKarin Mellitzer
Karin Mellitzer
ABAndrea Beck
Andrea Beck
Harald SourijHarald Sourij
Harald Sourij
Günther SilbernagelGünther Silbernagel
Günther Silbernagel
Background: PCSK9 antibodies strongly reduce LDL cholesterol. The effects of PCSK9 antibodies on triglyceride metabolism are less pronounced. The present study aimed to investigate in detail the effects of alirocumab on triglycerides, triglyceride-rich lipoproteins, and lipase regulators. Methods: A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were two visits at the study site: the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. Fat-tolerance tests, nuclear magnetic resonance spectroscopy, and enzyme-linked immunosorbent assays were performed to analyze lipid metabolism. Results: A total of 21 participants underwent the first and second investigation. Among these, two participants only received alirocumab twice and 19 patients completed the trial per protocol. All of them had atherosclerotic vascular disease. There was no significant effect of alirocumab treatment on fasting triglycerides, post-prandial triglycerides, or lipoprotein-lipase regulating proteins. Total, large, and small LDL particle concentrations decreased, while the HDL particle concentration increased (all p < 0.001). Mean total circulating PCSK9 markedly increased in response to alirocumab treatment (p < 0.001). Whereas PCSK9 increased more than three-fold in all 19 compliant patients, it remained unchanged in those two patients with two injections only. Conclusion: Significant effects of alirocumab on triglyceride metabolism were not detectable in the ALIROCKS trial. The total circulating PCSK9 concentration might be a useful biomarker to differentiate non-adherence from non-response to PCSK9 antibodies.

11 January 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
TMThomas Metzner
Thomas Metzner
DLDeborah R. Leitner
Deborah R. Leitner
GDGudrun Dimsity
Gudrun Dimsity
FGFelix Gunzer
Felix Gunzer
POPeter Opriessnig
Peter Opriessnig
Günther SilbernagelGünther Silbernagel
Günther Silbernagel
Background: Short-term effects of alirocumab on vascular function have hardly been investigated. Moreover, there is a scarce of reliable non-invasive methods to evaluate atherosclerotic changes of the vasculature. The ALIROCKS trial was performed to address these issues using standard ultrasound-based procedures and a completely novel magnetic resonance-based imaging technique. Methods: A total of 24 patients with an indication for treatment with PCSK9 antibodies were recruited. There were 2 visits to the study site, the first before initiation of treatment with alirocumab and the second after 10 weeks of treatment. The key outcome measures included the change of carotid vessel wall fractional anisotropy, a novel magnetic resonance-based measure of vascular integrity, and the changes of carotid intima-media thickness and flow-dependent dilatation of the brachial artery measured with ultrasound. Results: A total of 19 patients completed the trial, 2 patients stopped treatment, 3 patients did not undergo the second visit due to the COVID pandemic. All of them had atherosclerotic vascular disease. Their mean (standard deviation) LDL-cholesterol concentration was 154 (85) mg/dL at baseline and was reduced by 76 (44) mg/dL in response to alirocumab treatment (p < 0.001, n = 19). P-selectin and vascular endothelial growth factors remained unchanged. Flow-dependent dilatation of the brachial artery (+41%, p = 0.241, n = 18), carotid intima-media thickness (p = 0.914, n = 18), and fractional anisotropy of the carotid artery (p = 0.358, n = 13) also did not significantly change. Conclusion: Despite a nominal amelioration for flow-dependent dilatation, significant effects of short-term treatment with alirocumab on vascular function were not detectable. More work would be needed to evaluate, whether fractional anisotropy may be useful in clinical atherosclerosis research.

5 April 2025 in Computers in Biology and Medicine
Verified
Journal Article
Open access
SLStefan Leber
Stefan Leber
Felix GunzerFelix Gunzer
Felix Gunzer
EHEva Maria Hassler
Eva Maria Hassler
POPeter Opriessnig
Peter Opriessnig
TMThomas Metzner
Thomas Metzner
GRGernot Gernot Reishofer
Gernot Gernot Reishofer
Magnetic resonance (MR) diffusion tensor imaging (DTI) is a new, non-invasive method to investigate arterial vessel walls. High resolution diffusion weighted imaging (DWI) in combination with a two-dimensional (2D) diffusion gradient sampling scheme has recently been demonstrated as feasible for evaluating diffusivity in the vessel wall of human carotids. We aimed to identify associations of altered diffusivity in human carotids with presence or absence of cardiovascular disease, body mass index (BMI), sex and age in a clinical setting. In this single center case-control study we used DWI in combination with a 2D gradient in a 3 T MRI scanner to evaluate diffusivity parameters in carotid vessel walls of clinical patients with known cardiovascular disease (n = 17) and healthy controls (n = 21). We used a read-out segmented EPI (rs-EPI) sequence for DWI. A group comparison showed significantly decreased fractional anisotropy (FA) in patients older than 60 years (p < 0.001) and in patients with a BMI higher than 25 (p = 0.019). Patients with cardiovascular disease had higher values for mean diffusivity (p = 0.005) than patients without cardiovascular disease. A multiple linear regression analysis showed age and sex to be associated with FA. Two-dimensional vessel wall DTI of human carotids is feasible for clinical research. Besides patient age, we identified Sex, BMI, or the presence of cardiovascular disease as relevant factors for carotid vessel wall diffusivity. Decreased FA values might indicate early-stage atherosclerosis and vascular ageing.